Table 2 Characteristics of studies included in the meta-analysis
From: A gut microbial signature for combination immune checkpoint blockade across cancer types
Characteristics | Study | ||||||
|---|---|---|---|---|---|---|---|
CA209-538 (n = 106) | 2022_Simpson43 (n = 38) | 2021_McCulloch19 (n = 37)a | 2022_Lee18 (n = 165) | 2021_Andrews59 (n = 46) | 2018_Matson37 (n = 39) | 2017_Frankel60 (n = 39) | |
Country | Australia | Australia | USA | UK, Netherlands, Spain | USA | USA | USA |
Cancer type (%) | UGB (36%), GYN (34%), NEN (30%) | MEL (100%) | MEL (100%) | MEL (100%) | MEL (100%) | MEL (100%) | MEL (100%) |
ICB regimen (%) | CICB (100%) | CICB (100%) | Anti-PD-1 (100%) | CICB (33%), anti-PD-1 (61%), anti-CTLA-4 (7%) | CICB (100%) | Anti-PD-1 (100%) | CICB (62%), anti-PD-1 (36%), anti-CTLA-4 (3%) |
Response criteria | RECIST 1.1 | Pathological (INMC) | RECIST 1.1 | RECIST 1.1 | RECIST 1.1 | RECIST 1.1 | RECIST 1.1 |
Response | |||||||
CR | 3.8% | PathR: 84% | 5.4% | 13% | 11% | 5.1% | 13% |
PR | 21% | 51% | 26% | 52% | 33% | 36% | |
SD | 27% | 22% | 17% | 11% | 31% | 13% | |
PD | 28% | Non-pathR: 16% | 22% | 42% | 26% | 31% | 39% |
cPD | 20% | 0% | 1.8% | 0% | 0% | 0% | |
Stool collection kit | OMR-200 | EasySampler | EasySampler | LO—TF kits, MA—plain tube, NL—plain tube, LD—OMR-200, BL—OMR-200 | OMR-200 | EasySampler | NR |
DNA extraction kit | FastDNA soil | FastDNA feces | PowerSoil | LO—TF MagMAX, MA—TF MagMAX, LD—TF MagMAX, NL—TF MagMAX, BL—PowerFecal | PowerSoil | PowerFecal | Other |
Sequencer (bases per read) | NovaSeq (2 × 151) | NovaSeq (2 × 151) | NovaSeq (2 × 151) | NovaSeq (2 × 151) | NextSeq (2 × 151) | NextSeq (2 × 151) | HiSeq (2 × 100) |
Clean PE reads (millions) | |||||||
Minimum | 9.10 | 5.05 | 2.72 | 4.38 | 12.8 | 19.3 | 18.1 |
Median | 20.4 | 22.5 | 30.5 | 20.7 | 40.0 | 35.6 | 45.4 |
Maximum | 53.8 | 34.5 | 72.2 | 104 | 69.8 | 77.7 | 59.9 |
